<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619069</url>
  </required_header>
  <id_info>
    <org_study_id>iSTOP</org_study_id>
    <nct_id>NCT04619069</nct_id>
  </id_info>
  <brief_title>Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer</brief_title>
  <official_title>Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer: A Randomized Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type&#xD;
      of radiotherapy) to treat all the tumours that are present will improve outcomes or not&#xD;
      compared to drugs alone for patients who are negative on conventional imaging and positive on&#xD;
      PSMA PET scan&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eligible patients who enroll onto the study</measure>
    <time_frame>Through accrual completion, approx 2 years</time_frame>
    <description>The primary purpose of this feasibility study is to measure the proportion of patients who are willing to enter this randomized trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects and Effectiveness</measure>
    <time_frame>Through study completion, approx 5 years</time_frame>
    <description>An important secondary purpose is to measure the side effects and effectiveness of adding stereotactic radiotherapy to all sites of disease to intermittent hormone therapy compared to intermittent hormone therapy alone, using CTCAE v.5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent Hormone treatment (minimum of 8 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: SBRT to mets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent Hormone treatment (minimum of 8 months)&#xD;
+ SBRT to all sites of metastatic disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT to all sites of metastatic disease as seen on PSMA PET scan</description>
    <arm_group_label>Arm 2: SBRT to mets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone therapy</intervention_name>
    <description>Intermittent Hormone Therapy per physician discretion (Min. 8 months)</description>
    <arm_group_label>Arm 1: Standard of Care</arm_group_label>
    <arm_group_label>Arm 2: SBRT to mets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years.&#xD;
&#xD;
          2. Able to provide informed consent.&#xD;
&#xD;
          3. Histologic diagnosis of prostate adenocarcinoma.&#xD;
&#xD;
          4. ECOG performance status 0-1.&#xD;
&#xD;
          5. Stage IV hormone sensitive, synchronous or metachronous oligometastatic prostate&#xD;
             cancer as detected by PSMA PET-CT scan with no metastases visible on conventional&#xD;
             imaging (CT chest/abdomen/pelvis and bone scan +/- MRI) performed within 3 months of&#xD;
             starting ADT.&#xD;
&#xD;
          6. Up to a maximum of 3 PSMA avid areas of metastatic disease.&#xD;
&#xD;
          7. For patients with metachronous disease, there must be a documented PSA rise. For those&#xD;
             who had previous prostatectomy, PSA must be &gt; 0.2 ng/mL. For those who had previous&#xD;
             radical radiotherapy, PSA must have risen to at least 2 ng/mL above the nadir (Phoenix&#xD;
             definition). The primary tumor must be controlled, with no PSMA avid progression&#xD;
             within the primary prostate.&#xD;
&#xD;
          8. All sites of disease are amenable to and can be safely treated with SBRT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant comorbidities rendering patient not suitable for ADT and/or SBRT.&#xD;
&#xD;
          2. History of malignancy within the past 5 years, excluding non-melanoma skin cancer and&#xD;
             in-situ cancer.&#xD;
&#xD;
          3. Prior use of salvage or palliative intent ADT. Prior ADT use allowed only if it was&#xD;
             delivered neoadjuvantly, concurrently, or adjuvantly with curative-intent treatment to&#xD;
             the prostate or prostate bed (for patients with metachronous presentations), and at&#xD;
             least 12 months have elapsed.&#xD;
&#xD;
          4. Castrate resistant prostate cancer.&#xD;
&#xD;
          5. Evidence of spinal cord compression.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate Cancer Patients only. Males only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Cheung</last_name>
    <phone>4164805000</phone>
    <email>patrick.cheung@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Cheung</last_name>
      <phone>4164805000</phone>
      <email>patrick.cheung@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

